- Tous > Medicine Access and Rational Use > Better Medicines for Children
- Tous > Medicine Access and Rational Use > Pricing
- Mots-clés > access to medicines for children
- Mots-clés > affordability
- Mots-clés > availability
- Mots-clés > availability - children’s medicines
- Mots-clés > child‐specific medicines
- Mots-clés > Essential Medicines List for children - EMLc
- Mots-clés > health facility surveys
- Mots-clés > medicines for children
- Mots-clés > price comparison
- Mots-clés > prices / pricing policy
(2011; 7 pages) [French]
The continuous availability of affordable medicines for children is necessary for countries to reduce infant mortality, for attainment of Millennium Development Goal (MDG) 4 (UNDP, 2010). In recognition of the importance of availability of medicines for children to the success of MDG 4, the World Health Assembly (WHA) passed Resolution WHA60.20 in 2007. The resolution urges the inclusion of essential children’s medicines in national medicine lists, procurement and reimbursement schemes, as well as monitoring of prices (WHA, 2007).
In July and August 2010, the Ecumenical Pharmaceutical Network (EPN) conducted a study to determine the availability of essential medicines for children in church health facilities in Chad. The EPN study followed up on a 2007 World Health Organization (WHO) survey of children’s medicines’ availability in 14 African capitals. The WHO study revealed poor availability of medicines for children in both public and private medicine outlets (Robertson et al., 2009).
The objectives of the EPN study were to determine the availability of selected children’s medicines including antiretrovirals (ARVs); to describe facility-level practices that affect access to medicines and to document the opinions of health professionals regarding barriers to access.